SK Bioscience kicks off phase 3 clinical trial of its COVID-19 vaccine candidate
By Kim Han-joo
SEOUL, Aug. 30 (Yonhap) -- South Korean drugmaker SK Bioscience Co. said Monday it has begun the phase three clinical trial of its COVID-19 vaccine candidate.
GBP510, under development by SK Bioscience, a unit of the country's No. 2 family-controlled conglomerate SK Group, was administered to the first participant.
It comes nearly three weeks after the Ministry of Food and Drug Safety approved the trial, marking the country's first homegrown vaccine candidate to enter the last phase of clinical trial.
SK Bioscience aims to produce an interim result of its final stage of the clinical trial during the first quarter of next year before seeking final approval.
The clinical trial will compare GBP510 against the COVID-19 vaccine by AstraZeneca and Oxford University to view immunogenicity and safety, the ministry said.
The clinical trial will be simultaneously held in different countries by injecting some 3,000 participants with the vaccine candidate, while 990 others will get AstraZeneca doses.
U.S. B-1B strategic bomber returns to S. Korea as N.K. fires missile
(LEAD) N. Korea holds nuclear counterattack simulation drills; Kim urges perfect readiness: KCNA
Actor Yoo Ah-in to appear for questioning Friday over alleged drug use
American admits to train graffiti-related charges but calls himself artist
S. Korea expresses regret over 'distorted' reports on Yoon-Kishida summit
Yoon puts S. Korea-Japan relations back on track
Japan's removal of export curbs on S. Korea to boost supply chain stability, ease biz uncertainties
Yoon's summit with Biden to highlight S. Korea's 'pivotal' role in region: U.S. experts
(News Focus) Solution to forced labor issue shows Yoon's commitment to improving ties with Japan
Seoul's controversial plan for forced labor compensation reflects urgency of security partnership with Tokyo: experts